Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 12Lung Neoplasms 10Uterine Cervical Neoplasms 9Neoplasms 9Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Carcinoma 5Mesothelioma, Malignant 4Carcinoma, Hepatocellular 4Tongue Neoplasms 3Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Neoplasms 2Mesothelioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2

Interventions

ricolinostat 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Klatskin Tumor × Cisplatin × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡